All issues
Volume 24 (2009)
- Issue 6 Pages 572-
- Issue 5 Pages 468-
- Issue 4 Pages 384-
- Issue 2 Pages 96-
- Issue 1 Pages 28-
Volume 24, Issue 1
Displaying 1-5 of 5 articles from this issue
- |<
- <
- 1
- >
- >|
Feature articles “DDS formulation in clinical development” Editor : Yasuhiro Matsumura
-
Ken Kato2009 Volume 24 Issue 1 Pages 28-34
Published: 2009
Released on J-STAGE: April 23, 2009
JOURNAL FREE ACCESSNK105 is a polymer micelle that involves the paclitaxel. According to the results of the phase I study, recommended dosage is 150 mg/m2, and the dose limiting toxicity is neutropenia. Phase II study against gastric cancer was started.View full abstractDownload PDF (576K) -
Keiichi Fujiwara2009 Volume 24 Issue 1 Pages 35-37
Published: 2009
Released on J-STAGE: April 23, 2009
JOURNAL FREE ACCESSDoxil(liposomal doxorubicin) is a polyethylene glycol coated(PEG) liposomal doxorubicin(PLD). PEG coating enable the agent to be delivered to the target tissue without being caught by the macrophage. PLD can be accumulated in the tumor tissue, and then doxorubicin is released slowly. Tissue concentration of doxorubicin becomes higher without heightened the blood concentration of doxorubicin. This mechanism contributes the low incidence of adverse events of doxorubicin such as bone marrow suppression, hair loss, and cardiac toxicity. In this article the clinical features of PLD on ovarian cancer is discussed.View full abstractDownload PDF (183K) -
Kazuhiko Yamada2009 Volume 24 Issue 1 Pages 38-44
Published: 2009
Released on J-STAGE: April 23, 2009
JOURNAL FREE ACCESSAbraxane is a novel Cremophor EL-free nanoparticle albumin-bound paclitaxel. This formulation permits a higher paclitaxel concentration in solution, therefore, it allows for a higher dosage of paclitaxel in shorter infusion time without pre-medication.View full abstractDownload PDF (461K) -
Takashi Shimizu, Yasuki Kato2009 Volume 24 Issue 1 Pages 45-53
Published: 2009
Released on J-STAGE: April 23, 2009
JOURNAL FREE ACCESSClinical application of anti-tumor polymeric micellar drugs consisted with nanoparticles is on going. NC-6004 is cisplatin-incorporated micellar drug. The particle size of NC-6004 is small, which is approximately 30 nm. The particles are retained in blood flow a long time and sustain release of cisplatin. In terms of these characteristics, NC-6004 is expected to reduce the renal toxicity that is considered as one of the clinical issues of cisplatin therapy. NC-6004 is also expected to facilitate accumulation of cisplatin into tumor tissues by getting through pores in blood vessels of tumor tissues.
Phase I study of NC-6004 in patients with advanced cancer was conducted in UK. The results for the study were reviewed.View full abstractDownload PDF (482K) -
Yousuke Horita, Tetsuya Hamaguchi, Toshihiko Doi, Masaya Takanashi2009 Volume 24 Issue 1 Pages 54-61
Published: 2009
Released on J-STAGE: April 23, 2009
JOURNAL FREE ACCESSNK012 is a micellar drug that incorporates the CPT-11 active metabolite SN-38. Currently, CPT-11 is used for the treatment of a wide variety of cancer;however, it is expected that NK012 may show stronger antitumor effects of SN-38 than CPT-11. A phase I trial of NK012 was performed separately in the US and Japan, and the result of each trial showed that NK012 is well tolerated, suggesting its clinical usefulness.
It is anticipated that the subsequent phase II and III trials will demonstrate the advantages of NK012 as a drug delivery system.View full abstractDownload PDF (480K)
- |<
- <
- 1
- >
- >|